Multicenter randomized trial comparing zoladex with zoladex plus flutamide in the treatment of advanced prostate cancer. Survival update

Abstract

589 patients with advanced prostate cancer (distant metastasis is present, any tumor category) or locally advanced prostate cancer (tumor stage 3 or 4) were randomized to receive either a subcutaneous depot of 3.6 mg Zoladex monthly or this dose of Zoladex in combination with an oral dose of 250 mg of Flutamide twice a day. The two treatment groups, composed of 571 patients who could be evaluated, were comparable with respect to major demographic